An anonymous reader quotes the New York Times:
About 90 percent of C. auris strains are resistant to at least one drug, and 30 percent are resistant to two or more of the three major classes of antifungal drugs. However, on Tuesday, the C.D.C. confirmed that it has learned in the last month of the first known cases in the United States of so-called “pan-resistant” C. auris — a strain resistant to all major antifungals, said Dr. Tom Chiller, head of the agency’s fungal division, in an interview.
Such cases have been seen in several countries, including India and South Africa, but the two new cases, from New York State, have not been reported previously. Dr. Chiller said that it appeared that, in each case, the germ evolved during treatment and became pan-resistant, confirming a fear that the infection will continue to develop more effective defenses. “It’s happening and it’s going to happen,” Dr. Chiller said. “That’s why we need to remain vigilant and rapidly identify and control these infections.”
It often has been hard to gather details about the path of C. auris because hospitals and nursing homes have been unwilling to publicly disclose outbreaks or discuss cases, creating a culture of secrecy around the infection. States have kept confidential the locations of hospitals where outbreaks have occurred, citing patient confidentiality and a risk of unnecessarily scaring the public.
In an interview with CBS News, the reporter stressed that while this was a serious issue, especially in hospitals, it’s not yet a threat to the general public:
“The people who are susceptible are people with weakened immune systems, the infirm, older folks in hospitals,” Matt Richtel said. “So let me put the finest possible point on this: the general public walking down the street [is] not going to be felled by this. You’re not gonna get it walking to Walmart. You’re not going to get it in your house.”
Read more of this story at Slashdot.